期刊
SCIENCE
卷 340, 期 6132, 页码 626-630出版社
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.1236062
关键词
-
资金
- National Brain Tumor Society
- National Institutes of Health [1R01NS080944-01, U54CA143798]
- Leon Levy Foundation
- James S. McDonnell Foundation
- American Brain Tumor Association
- Lymphoma Research Foundation
- American Cancer Society
- American Society of Clinical Oncology
The recent discovery of mutations in metabolic enzymes has rekindled interest in harnessing the altered metabolism of cancer cells for cancer therapy. One potential drug target is isocitrate dehydrogenase 1 (IDH1), which is mutated in multiple human cancers. Here, we examine the role of mutant IDH1 in fully transformed cells with endogenous IDH1 mutations. A selective R132H-IDH1 inhibitor (AGI-5198) identified through a high-throughput screen blocked, in a dose-dependent manner, the ability of the mutant enzyme (mIDH1) to produce R-2-hydroxyglutarate (R-2HG). Under conditions of near-complete R-2HG inhibition, the mIDH1 inhibitor induced demethylation of histone H3K9me3 and expression of genes associated with gliogenic differentiation. Blockade of mIDH1 impaired the growth of IDH1-mutant-but not IDH1-wild-type-glioma cells without appreciable changes in genome-wide DNA methylation. These data suggest that mIDH1 may promote glioma growth through mechanisms beyond its well-characterized epigenetic effects.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据